Science – Etern Therapeutics

ETERN has Developed Novel Protein
LLPS Technology Platform to Drug "Undruggable" Targets

"Undruggable" Targets

  • Transcriptional Factors
  • Phosphatases
  • Protein-Protein Interaction
  • Ras, etc.

Why Target “Undruggable” ?

Strong Disease Link

Untouched Realm

Novel Mechanism

Based on Deep Understanding of STRUCTURE DYNAMICS, We Combine Strong Expertise on Hit Generation, Structural Biology, CADD and MedChem to Target Undruggable Proteins and Deliver Novel Drug Candidates

Liquid-Liquid Phase Separation (LLPS):

  • Biomolecular condensates, an emerging paradigm of cellular organization
  • Involved in various critical biological functions
  • Implicated in many human diseases such as neurodegenerative diseases and cancers

Many “undruggable” targets undergo LLPS to activate their biological functions

LLPS of “undruggable” targets can be regulated by small molecule inhibitors

Through integrated screening approaches, we have been successful in identifying small molecules regulating protein LLPS